Folks taking weight-loss drugs like Wegovy or Zepbound might think they've found a shortcut to better health. But they still ...

Blockbuster weight loss drugs have been arguably the biggest health story of the last several years — and there are no signs ...

People taking the experimental drug amycretin were found to lose almost twice as much weight over a 12-week period as the ...

Looking for successors to the blockbuster GLP-1 obesity drugs, companies like Novo Nordisk and Eli Lilly are testing amylin ...

Data from an early stage clinical trial suggests Novo Nordisk’s new weight loss pill amycretin could produce greater and more ...

Although women lost more weight, all participants saw significant decreases in total body weight on all doses of the medication.

Results from 4 studies revealed that women lost more weight on average than men when taking tirzepatide — but they also ...

Extreme hunger is common after people stop taking GLP-1 drugs like Ozempic and Wegovy, but health experts say these simple ...

A recent study estimated that Wegovy’s label expansion beyond obesity could push Medicare spending to $145 billion annually, ...

Frustrated Zepbound users have been advocating for vial options for ... Lilly and Novo Nordisk, the maker of Ozempic and ...

A recent announcement by Eli Lilly suggests that the company understands the economic conundrum some patients face. Per a ...